{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:21:32Z","timestamp":1792516892571,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtm.2025.101580","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:49:44Z","timestamp":1756482584000},"page":"101580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Landscape of ex vivo gene therapies: Technological trends and future prospects"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-8539","authenticated-orcid":false,"given":"Aline","family":"Almeida-Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Hern\u00e1n","family":"Bonamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Hugo","family":"Villa\u00e7a Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Praia","family":"Borges Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Danowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais Pereira","family":"Cat\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna do Nascimento e Silva","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Torres","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Lemos","family":"Gottgtroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"de Miranda Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique Menegaci","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"de Castro Fialho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101580_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.omtm.2021.11.003","article-title":"Current landscape of clinical development and approval of advanced therapies","volume":"23","author":"Iglesias-Lopez","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101580_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12033-024-01070-4","article-title":"The Future of Gene Therapy: A Review of In Vivo and Ex Vivo Delivery Methods for Genome Editing-Based Therapies","volume":"67","author":"Volodina","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101580_bib3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.hoc.2022.05.001","article-title":"Evolution of Gene Therapy, Historical Perspective","volume":"36","author":"Malech","year":"2022","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.omtm.2025.101580_bib4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101580_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtm.2025.101580_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.gpeds.2024.100196","article-title":"Gene therapy for rare haematological and neurometabolic paediatric diseases","volume":"9","author":"Gallo","year":"2024","journal-title":"Global Pediatrics"},{"key":"10.1016\/j.omtm.2025.101580_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.32033","article-title":"Gene-targeted therapies: Overview and implications","volume":"193","author":"Brooks","year":"2023","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"10.1016\/j.omtm.2025.101580_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/vox.13612","article-title":"Current state of gene therapy in sickle cell disease","volume":"119","author":"Tang","year":"2024","journal-title":"Vox Sang."},{"key":"10.1016\/j.omtm.2025.101580_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib11","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41434-019-0074-7","article-title":"Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine","volume":"27","author":"Elverum","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-024-01215-0","article-title":"Do cutting-edge CAR-T-cell therapies cause cancer? What the data say","volume":"629","author":"Willyard","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101580_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.techfore.2010.07.016","article-title":"The development of technology foresight: A review","volume":"77","author":"Miles","year":"2010","journal-title":"Technol. Forecast. Soc. Change"},{"key":"10.1016\/j.omtm.2025.101580_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1142\/S1363919609002297","article-title":"Practices of strategic foresight in biotech companies","volume":"13","author":"Mietzner","year":"2009","journal-title":"Int. J. Innov. Manage."},{"key":"10.1016\/j.omtm.2025.101580_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/09537325.2012.715487","article-title":"Strategic foresight: matching environmental uncertainty","volume":"24","author":"Vecchiato","year":"2012","journal-title":"Technol. Anal. Strat. Manag."},{"key":"10.1016\/j.omtm.2025.101580_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.techfore.2015.11.002","article-title":"Corporate foresight: An emerging field with a rich tradition","volume":"101","author":"Rohrbeck","year":"2015","journal-title":"Technol. Forecast. Soc. Change"},{"key":"10.1016\/j.omtm.2025.101580_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/humc.2018.201","article-title":"The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost","volume":"30","author":"Shukla","year":"2019","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101580_bib20","series-title":"Cell and Gene Therapy: Current Landscape, Emerging Trends and Future Prospects","author":"Roy","year":"2024"},{"key":"10.1016\/j.omtm.2025.101580_bib21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ymthe.2019.09.002","article-title":"The Landscape of Early Clinical Gene Therapies outside of Oncology","volume":"27","author":"Ritti\u00e9","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jgg.2024.07.004","article-title":"Gene therapy and gene editing strategies in inherited blood disorders","volume":"51","author":"Song","year":"2024","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.omtm.2025.101580_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtm.2025.101580_bib24","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.ymthe.2021.08.017","article-title":"ASGCT\u2019s new landscape reports: A comprehensive data resource","volume":"29","author":"Foss-Campbell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The Emerging Landscape of Immune Cell Therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101580_bib26","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","article-title":"Development and clinical translation of ex vivo gene therapy","volume":"20","author":"Wu","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.omtm.2025.101580_bib27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/ph16101416","article-title":"Current State of Human Gene Therapy: Approved Products and Vectors","volume":"16","author":"Shchaslyvyi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtm.2025.101580_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.21037\/atm-22-3882","article-title":"A new era of gene and cell therapy for cancer: a narrative review","volume":"11","author":"Wang","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib29","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","article-title":"The state of cell and gene therapy in 2023","volume":"31","author":"Chancellor","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70056","article-title":"Gene and cell therapy of human genetic diseases: Recent advances and future directions","volume":"28","author":"Cetin","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023\u2014an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omtm.2025.101580_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101580_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12247-023-09713-w","article-title":"The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19","volume":"18","author":"de Almeida Oliveira","year":"2023","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.omtm.2025.101580_bib35","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2025.101580_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib38","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","article-title":"Progress and challenges in viral vector manufacturing","volume":"25","author":"van der Loo","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101580_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex Vivo Cell-Based CRISPR\/Cas9 Genome Editing for Therapeutic Applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtm.2025.101580_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omtm.2025.101580_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454747","article-title":"Cutting-edge approaches to B-cell depletion in autoimmune diseases","volume":"15","author":"Robinson","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.911919","article-title":"TIGIT as a Promising Therapeutic Target in Autoimmune Diseases","volume":"13","author":"Yue","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266980","article-title":"BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity","volume":"17","author":"Hickman","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101580_bib47","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2025.101580_bib48","article-title":"Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib49","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omtm.2025.101580_bib50","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers17030413","article-title":"Adoptive T Cell Therapy Targeting MAGE-A4","volume":"17","author":"Chandora","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omtm.2025.101580_bib53","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.32604\/or.2024.056565","article-title":"Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development","volume":"32","author":"Zheng","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.omtm.2025.101580_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omtm.2025.101580_bib55","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtm.2025.101580_bib56","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib61","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib62","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.seminhematol.2024.07.003","article-title":"Tuning CAR T-cell therapies for efficacy and reduced toxicity","volume":"61","author":"Blud","year":"2024","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.omtm.2025.101580_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtm.2025.101580_bib65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101580_bib66","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.3390\/cancers14215351","article-title":"Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe","volume":"14","author":"Castiello","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omtm.2025.101580_bib67","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101580_bib68","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101580_bib69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib70","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib71","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.omtm.2025.101580_bib73","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib74","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.3390\/ijms25042243","article-title":"Emerging Gene Therapeutics for Epidermolysis Bullosa under Development","volume":"25","author":"Bischof","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101580_bib75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17460751.2025.2480003","article-title":"The future of ex vivo hematopoietic stem cell gene editing: what\u2019s next","volume":"20","author":"Cavazza","year":"2025","journal-title":"Regen. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib76","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib77","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101580_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn1902","article-title":"The translational gap for gene therapies in low- and middle-income countries","volume":"16","author":"Doxzen","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101580_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-023-00425-x","article-title":"A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies","volume":"31","author":"Saleh","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101580_bib80","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-024-07800-7","article-title":"A roadmap for affordable genetic medicines","volume":"634","author":"Kliegman","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101580_bib81","article-title":"Clinical trials to gene therapy development and production in Brazil: a review","volume":"43","author":"Morales Saute","year":"2025","journal-title":"Lancet Reg. Health. Am."},{"key":"10.1016\/j.omtm.2025.101580_bib82","article-title":"Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit","volume":"20","author":"Johanna","year":"2023","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.omtm.2025.101580_bib83","article-title":"Cost-Effective Strategies for CAR-T Cell Therapy Manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib84","article-title":"Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies","volume":"11","author":"S","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtm.2025.101580_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtm.2025.101580_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtm.2025.101580_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtm.2025.101580_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383894","article-title":"Universal CAR 2.0 to overcome current limitations in CAR therapy","volume":"15","author":"Schlegel","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101580_bib89","series-title":"A primeira vacina 100% brasileira contra a Covid-19: a conquista de Bio-Manguinhos\/Fiocruz (Editora Fiocruz)","year":"2022"},{"key":"10.1016\/j.omtm.2025.101580_bib90","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jnci\/djad082","article-title":"Clinical development of new drugs for adults and children with cancer, 2010-2020","volume":"115","author":"Arf\u00e8","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omtm.2025.101580_bib91","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.stem.2010.05.012","article-title":"Pharma\u2019s Developing Interest in Stem Cells","volume":"6","author":"McKernan","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtm.2025.101580_bib92","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrd4232","article-title":"Regulatory watch: Where do new medicines originate from in the EU?","volume":"13","author":"Lincker","year":"2014","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:30:45Z","timestamp":1776198645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2329050125001755"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101580","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Landscape of ex vivo gene therapies: Technological trends and future prospects","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101580"}}